4D Molecular Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 12.78 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 706.02M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company’s lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
Details
| Name | 4D Molecular Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 196 |
| Founded | 2013 |
| Ipo Date | 2020-12-11 |
| Ceo | David Kirn |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 23.00 |
| Isin | US35104E1001 |
| Cusip | 35104E100 |
| Cik | 0001650648 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. David H. Kirn M.D. | Co-Founder, President, Chief Executive Officer and Director |
| Dr. John F. Milligan Ph.D. | Executive Chairman |
| Kristian Humer M.B.A. | Chief Financial Officer and Principal Financial and Accounting Officer |
| Dr. Fariborz Kamal Ph.D. | Chief Technical Advisor |
| Theresa Janke | Co-Founder and Chief of Staff |
| Julian Pei | Head of Investor Relations and Corporate Finance |
| Dr. Katy Barglow Ph.D. | Chief Technical Officer |
| Dr. Scott P. Bizily J.D., Ph.D. | Chief Legal Officer and Corporate Secretary |
| Dr. An Song Ph.D. | Chief Translational Medicine Advisor |
| Dr. Noriyuki Kasahara M.D., Ph.D. | Chief Scientific Advisor |
Contact
| Address | 5858 Horton Street, Suite 455, EmeryVille, California 94608, United States |
| Phone | 510 505 2680 |
| Website | https://www.4dmoleculartherapeutics.com |